Electrochemotherapy: a valid treatment for Gorlin-Goltz syndrome.

ACTA DERMATOVENEROLOGICA CROATICA The Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma (BCC), has a variable prevalence, estimated from 1/57,000 to 1:256,000 inhabitants (1). It is a rare autosomal dominant disorder due to a genetic mutation in the PTCH tumor suppressor gene localized to 9q22.3 chromosome (2). In order to make a diagnosis of Gorlin-Goltz syndrome, some diagnostic criteria have to be taken into account. The most important criteria are the presence of pigmented BCCs, odontogenic keratocysts, palmar and/or plantar pits, and ectopic calcifications of the falx cerebri. Together with these major criteria, more than 100 minor clinical signs have been described. Diagnosis can be established when two major or one major and two minor criteria are present (3) (Table 1). Basal cell carcinomas are seen in 50%-97% of all cases. Some differences have been described beActa Dermatovenerol Croat 2013;21(2):132-134 Letter to the editor